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Abstract
Underestimating antimicrobial use based on days of therapy (DOT) is recognized for certain antimicrobial agents. We investigated the differ-
ence betweenDOT and therapeutic drug monitoring (TDM)–based exposure days in estimating vancomycin use and demonstrated that DOT
may underestimate vancomycin exposure by ∼10%.
(Received 26 September 2018; accepted 21 December 2018)
Tracking antimicrobial consumption is vital for effective antimicro-
bial stewardship. Days of therapy (DOT) is a measure commonly
used in the United States to assess intravenous antimicrobial con-
sumption in inpatient settings based on better applicability to the
pediatric population and independence from antimicrobial
dosage.1–3 However, DOT may be unsuitable for certain antimicro-
bials because this method may underestimate their use, especially
when intermittent doses are administered to elderly patients or
those with impaired renal function. DOT measures antimicrobial
administration but not antimicrobial exposure. Recently, the
National Healthcare Safety Network (NHSN) antimicrobial use
(AU) module began tracking antimicrobial use with a different
denominator (ie, per 1,000 days present),2 but the optimal method
has not been determined.
Length of therapy (LOT) may be more effective for measuring
vancomycin use, especially in inpatients with impaired renal func-
tion, because it reflects the actual days of exposure rather than the
days of antimicrobial administration. LOT for intermittent antimi-
crobial dosing is conventionally calculated as the number of days
from the start to the end of antimicrobial administration compris-
ing a single continuous treatment course.4
However, calculating the days of antimicrobial exposure with
intermittent dosing may be challenging. The study institution has
been performing therapeutic drug monitoring (TDM) of vancomy-
cin twice weekly since 2014 because once-weekly TDMmay be inad-
equate to detect a quick rise in trough concentrations exceeding
the therapeutic range among hospitalized patients. Combining
frequent TDM and measurements of vancomycin trough concen-
trationsmay enable us to estimate vancomycin exposuremore accu-
rately. The purpose of this study was to calculate TDM-based
exposure days and to compare the results withDOT for vancomycin
in a tertiary-care center.
Methods
This retrospective observational study used data collected from
April 2012 to March 2018 at Tokyo Metropolitan Tama Medical
Center, a tertiary-care center in Japan. During the study period,
data on the monthly patient days, monthly intravenous vancomy-
cin use, and frequency of TDM were collected.
The DOT measurements were based on facility-wide, monthly
medication data. We counted only the day on which vancomycin
was administered intravenously as a DOT, in accordance with the
NHSN AUmodule definition.2 The TDM-based exposure days for
facility-wide vancomycin use was measured as described below,
based on TDM by a clinical pharmacist at the study institution.
We determined the exposure days as the number of days from
the start of vancomycin administration to the last day of vancomy-
cin exposure as confirmed by twice weekly TDM. For TDM-based
exposure days, the last exposure day was defined as either the last
actual day of vancomycin administration or the last vancomycin
trough concentration obtained on the planned final date of vanco-
mycin therapy for an established infection requiring long-term
antimicrobial therapy (eg, bloodstream infection). For patients
without vancomycin TDM due to the short duration of their
therapy (eg, as part of empiric therapy in the first 72 hours followed
by prompt discontinuation or streamlining), the exposure days
were counted as the days of exposure consisting of the number
of days of actual vancomycin administration as with the measure-
ment of DOT. At the study institution, clinical pharmacists per-
form TDM for all patients on vancomycin to assist primary care
providers in accordance with the vancomycin TDM guidelines.5
Moreover, the DOT data and the TDM-based exposure days were
compared based on patients’ renal function. We stratified the
monthly DOT and TDM-based exposure days into 4 groups
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according to creatinine clearance (CrCl) using Cockcroft-Gault
equations: (1) CrCl ≥ 60 mL/min, (2) CrCl 30–60 mL/min, (3)
CrCl < 30 mL/min, and (4) dialysis.
The paired t test was used to assess the differences between
DOT and TDM-based exposure days. For the statistical analysis,
we used Stata version 15.2 software (StataCorp, College Station,
Texas). The institutional review board at the study institution
approved the study.
Results
Appendices 1 and 2 show the details of TDM and vancomycin use
in terms of DOT and TDM-based exposure days during the study
period. In general, the median patient days per month were stable
at∼19,000. The number of patients receiving at least 1 dose of van-
comycin increased during the study period. Since 2014, TDM has
been performed twice weekly at the study institution in most
patients, except those on a short course of therapy.
The mean monthly vancomycin use was 343.5 DOT (standard
deviation [SD], 87.3) and 383.8 TDM-based exposure days (SD,
88.9). The difference between DOT and TDM-based exposure
days was−40.3 days (SD, 16.9; P< .001), and the relative difference
between DOT and TDM-based exposure days was −10.9%
(SD, 4.9%).
Among the 4 renal function groups, DOT, TDM-based expo-
sure days, and the absolute and relative differences between the
2 methods varied. For the CrCl ≥ 60 mL/min group, DOT was
187.5 days (SD, 56.1); TDM-based exposure days was 190.7
days (SD, 56.1); the absolute difference between the 2 methods
was −3.2 days (SD, 3.9) (P < .001); and the relative difference
was −1.8% (SD, 2.7%). For the 60 > CrCl ≥ 30 mL/min group,
DOT was 99.4 days (SD, 42.0); TDM-based exposure days was
103.8 days (SD, 41.7); the absolute difference between the 2methods
was −4.4 days (SD, 4.9; P < .001); and the relative difference was
−5.2% (SD, 7.2%). For the CrCl < 30 mL/min group, DOT was
27.4 days (SD, 17.5); TDM-based exposure days was 36.7 days
(SD, 20.5); the absolute difference between the 2 methods was
−9.3 days (SD, 7.3) (P < .001); and the relative difference was
−25.9% (SD, 18.9%). And for the dialysis group, DOT was 27.7 days
(SD, 15.5); TDM-based exposure days was 50.7 days (SD, 26.9), the
absolute difference between the 2methods was−23.0 days (SD, 14.1;
P < .001); and the relative difference was −44.8% (SD, 12.4%). The
details of vancomycin exposure among for each renal function group
are shown in Table 1.
Discussion
The 2 measures of vancomycin exposure differed significantly; the
DOT-based data underestimated vancomycin exposure by ∼10%
compared with TDM-based exposure days, which measured only
the days of actual exposure. A further difference in vancomycin
exposure among patients with CrCl <30 mL/min and those with
dialysis was observed, suggesting that using TDM-based exposure
days is a better method of assessing the actual duration of exposure
in patients with impaired renal function. The difficulty of using
exposure days as a measure is its inadequacy to determine the days
of exposure between each period of antimicrobial administration,
especially when vancomycin is administered at irregular intervals
due to renal dysfunction. Although a previous study demonstrated
the use of LOT based on the prespecified criteria,4 the method
described did not significantly differ from DOT. In contrast, the
method used here has the advantage of calculating exposure days
based on more frequent assessment of TDM with vancomycin
serum concentration values, enabling us to confirm whether the
patients were exposed to vancomycin even when the dosing inter-
vals were irregular or several days apart. Although TDM-based
exposure days probably correlate with DOT, this measure may
bemore suitable for patients with lower creatinine clearance, elderly
patients with labile renal function or intensive care units where
significant fluctuation in DOT measurement is expected.
Table 1. Details of Vancomycin Use Calculated by Days of Therapy and TDM-Based Exposure Days Among Each Estimated Renal Function
Variablea 2012 2013 2014 2015 2016 2017
Monthly DOT
CrCl ≥ 60 mL/min 144.0 (103.5, 155.0) 154.5 (134.3, 176.8) 183.5 (142.3, 199.8) 223.5 (195.3, 257.3) 202.0 (181.0, 256.0) 201.0 (173.3, 224.8)
CrCl 30–60 mL/min 77.0 (67.0, 93.8) 77.0 (66.8, 107.3) 78.5 (56.0, 114.0) 122.5 (99.3, 163.3) 105.5 (84.5, 127.3) 100.0 (75.8, 144.0)
CrCl < 30 mL/min 14.5 (10.8, 24.5) 14.0 (9.8, 26.5) 19.5 (12.5, 27.5) 24.0 (17.5, 34.8) 45.0 (36.5, 57.0) 42.0 (17.5, 49.5)
Dialysis 13.5 (8.8, 23.3) 22.5 (12.8, 30.8) 33.0 (22.5, 40.3) 23.5 (17.8, 33.0) 38.0 (25.3, 42.8) 32.5 (23.0, 37.5)
Monthly
TDM-based ExD
CrCl ≥ 60 mL/min 145.0 (108.3, 160.8) 158.0 (137.3, 177.5) 188.5 (154.8, 201.3) 227.5 (195.8, 257.8) 202.5 (182.5, 257.0) 202.5 (175.3, 227.8)
CrCl 30–60 mL/min 84.0 (71.5, 102.0) 78.0 (68.3, 111.8) 86.0 (63.0, 130.3) 128.0 (100.5, 162.5) 106.0 (86.3, 135.8) 103.5 (86.5, 144.8)
CrCl < 30 mL/min 28.0 (16.8, 38.3) 22.5 (21.0, 36.3) 26.5 (16.0, 34.8) 35.0 (22.8, 53.3) 53.5 (40.3, 65.5) 52.5 (22.3, 66.5)
Dialysis 30.0 (21.8, 54.5) 40.5 (28.0, 59.5) 63.5 (35.5, 78.8) 43.0 (38.0, 51.8) 50.5 (37.0, 85.5) 52.0 (39.5, 69.5)
Relative difference between DOT and TDM-based ExD, %
CrCl ≥ 60 mL/min −1.7 (−4.5, −1.0) −1.4 (−3.4, 0.0) −1.7 (−2.4, −1.2) −0.2 (−1.9, 0.0) −0.5 (−1.0, −0.2) −0.9 (−1.7, −0.4)
CrCl 30−60 mL/min −6.4 (−8.2, −1.4) −2.7 (−4.9, −1.4) −6.7 (−12.5, −3.7) −0.5 (−2.8, 0.0) −2.2 (−7.3, −1.3) −1.2 (−2.3, 0.0)
CrCl < 30 mL/min −37.9 (−55.1, −28.8) −35.7 (−53.1, −29.1) −19.4 (−39.1, 0.0) −23.1 (−36.4, −9.4) −11.7 (−19.0, −9.1) −20.6 (−26.0, −14.4)
Dialysis −57.2 (−62.1, −53.1) −47.7 (−53.6, −36.6) −47.5 (−52.3, −44.1) −46.5 (−49.1, −36.9) −37.9 (−45.1, −28.2) −41.6 (−49.0, −33.0)
Note. IQR, interquartile range; CrCl, creatinine clearance (Cockcroft-Gault equations); DOT, days of therapy; ExD, exposure days; TDM, therapeutic drug monitoring.
aAll data reported as median (IQR).
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Our study has several limitations. Although the study institu-
tion performs vancomycin TDM twice weekly, the ideal fre-
quency is unclear. We were unable to collect exposure days
data automatically, and the process was labor intensive. The cur-
rent study included days with subtherapeutic levels of vancomy-
cin in the total exposure days due to the impossibility of assessing
the period of subtherapeutic exposure via twice weekly TDM.
Eliminating these days from the calculation may improve
accuracy.
In conclusion, vancomycin exposure was ∼10% lower when
assessed using DOT than when using TDM-based exposure days.
However, depending on the patient population and density of
vancomycin use, additional benchmarks including TDM-based
exposure days may be important for calculating the days of vanco-
mycin exposure accurately.
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Appendix 1.: Details of vancomycin therapeutic drug monitoring and use by days of therapy and exposure days
2012 2013 2014 2015 2016 2017
A monthly patient-days, median (IQR) 19146 (18843, 19670) 19337 (19062, 19550) 18726 (18301, 19154) 19198 (18947, 19575) 19238 (18875, 19409) 18649 (18377, 19028)
A monthly DOT, median (IQR) 249.5 (231.8, 273.0) 283.5 (254.0, 327.3) 321.0 (293.3, 345.0) 413.0 (344.8, 452.5) 420.0 (383.3, 440.8) 384.0 (342.3, 442.8)
A monthly TDM-based ExD , median (IQR) 295.0 (258.5, 326.0) 326.0 (294.8, 363.8) 378.0 (342.8, 392.3) 464.0 (366.5, 501.5) 452.5 (425.5, 488.5) 426.5 (381.8, 475.5)
Relative difference between DOT and
TDM-based ExD , %, median (IQR)
−13.7 (−16.8, −11.6) −12.2 (−13.4, −10.7) −13.3 (−16.1, −9.7) −7.6 (−8.9, −5.9) −8.0 (−10.8, −5.1) −8.8 (−10.5, −7.1)
Total number of patients per month who received
at least one dose of vancomycin, median (IQR)
40.5 (37.3, 43.8) 50.5 (45.8, 53.3) 52.5 (47.5, 57.3) 65.0 (56.0, 73.3) 66.5 (59.0, 70.3) 68.0 (61.8, 74.5)
Total number of patients per month who received at
TDM at least once, median (IQR)
23.0 (20.5, 24.0) 25.0 (22.0, 31.0) 28.5 (25.0, 33.0) 34.5 (29.0, 41.8) 37.5 (34.3, 40.3) 37.0 (30.3, 41.0)
Monthly number of TDM performed, median (IQR) 50.5 (45.8, 59.3) 59.0 (52.5, 68.3) 73.5 (66.8, 81.3) 102.5 (87.8, 117.5) 118.0 (107.3, 125.0) 111.0 (97.8, 123.5)
Weekly number of TDM performed for
individual patients, median (IQR)
1.24 (0.88, 1.62) 1.40 (0.88, 1.75) 1.40 (1.00, 2.00) 1.75 (1.17, 2.20) 1.75 (1.40, 2.33) 1.75 (1.40, 2.33)
Total number of patients per month
who received intermittent doses of
vancomycin, median (IQR)
6.0 (5.8, 8.0) 8.5 (7.0, 9.3) 10.0 (8.8, 13.0) 7.5 (5.8, 9.3) 8.5 (7.8, 11.5) 10.0 (6.3, 12.0)
Vancomycin trough concentration,
mg/L, median (IQR)
15.3 (11.3, 18.7) 15.1 (11.7, 18.4) 13.6 (10.5, 17.3) 13.0 (10.0, 16.1) 12.9 (9.8, 15.6) 12.4 (8.8, 15.6)








































































































Note. DOT; days of therapy, TDM; therapeutic drug monitoring, ExD, exposure days.
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